» Articles » PMID: 21245263

Human Cardiomyopathy Mutations Induce Myocyte Hyperplasia and Activate Hypertrophic Pathways During Cardiogenesis in Zebrafish

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2011 Jan 20
PMID 21245263
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

To assess the effects during cardiac development of mutations that cause human cardiomyopathy, we modeled a sarcomeric gene mutation in the embryonic zebrafish. We designed morpholino antisense oligonucleotides targeting the exon 13 splice donor site in the zebrafish cardiac troponin T (tnnt2) gene, in order to precisely recapitulate a human TNNT2 mutation that causes hypertrophic cardiomyopathy (HCM). HCM is a disease characterized by myocardial hypertrophy, myocyte and myofibrillar disarray, as well as an increased risk of sudden death. Similar to humans with HCM, the morphant zebrafish embryos displayed sarcomere disarray and there was a robust induction of myocardial hypertrophic pathways. Microarray analysis uncovered a number of shared transcriptional responses between this zebrafish model and a well-characterized mouse model of HCM. However, in contrast to adult hearts, these embryonic hearts developed cardiomyocyte hyperplasia in response to this genetic perturbation. The re-creation of a human disease-causing TNNT2 splice variant demonstrates that sarcomeric mutations can alter cardiomyocyte biology at the earliest stages of heart development with distinct effects from those observed in adult hearts despite shared transcriptional responses.

Citing Articles

Modeling of large-scale hoxbb cluster deletions in zebrafish uncovers a role for segmentation pathways in atrioventricular boundary specification.

Hu P, Wang B, Jin D, Gu Y, He H, Meng X Cell Mol Life Sci. 2023; 80(11):317.

PMID: 37801106 PMC: 11072906. DOI: 10.1007/s00018-023-04933-2.


Glia maturation factor-γ is required for initiation and maintenance of hematopoietic stem and progenitor cells.

Li H, Luo Q, Cai S, Tie R, Meng Y, Shan W Stem Cell Res Ther. 2023; 14(1):117.

PMID: 37122014 PMC: 10150485. DOI: 10.1186/s13287-023-03328-1.


Developmental programming: adverse sexually dimorphic transcriptional programming of gestational testosterone excess in cardiac left ventricle of fetal sheep.

Ramamoorthi Elangovan V, Saadat N, Ghnenis A, Padmanabhan V, Vyas A Sci Rep. 2023; 13(1):2682.

PMID: 36792653 PMC: 9932081. DOI: 10.1038/s41598-023-29212-9.


Live cell screening identifies glycosides as enhancers of cardiomyocyte cell cycle activity.

Magadum A, Renikunta H, Singh N, Estaras C, Kishore R, Engel F Front Cardiovasc Med. 2022; 9:901396.

PMID: 36225954 PMC: 9549374. DOI: 10.3389/fcvm.2022.901396.


What Causes Hypertrophic Cardiomyopathy?.

Maron B, Wang R, Carnethon M, Rowin E, Loscalzo J, Maron B Am J Cardiol. 2022; 179:74-82.

PMID: 35843734 DOI: 10.1016/j.amjcard.2022.06.017.


References
1.
Berriz G, Beaver J, Cenik C, Tasan M, Roth F . Next generation software for functional trend analysis. Bioinformatics. 2009; 25(22):3043-4. PMC: 2800365. DOI: 10.1093/bioinformatics/btp498. View

2.
Knollmann B, Kirchhof P, Sirenko S, Degen H, Greene A, Schober T . Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res. 2003; 92(4):428-36. DOI: 10.1161/01.RES.0000059562.91384.1A. View

3.
Song L, Alcalai R, Arad M, Wolf C, Toka O, Conner D . Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2007; 117(7):1814-23. PMC: 1904315. DOI: 10.1172/JCI31080. View

4.
Granata R, Trovato L, Gallo M, Destefanis S, Settanni F, Scarlatti F . Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res. 2009; 83(2):303-12. DOI: 10.1093/cvr/cvp090. View

5.
Cha H, Jeong H, Jang S, Kim J, Yang D, Oh J . Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med. 2009; 42(1):61-8. PMC: 2811821. DOI: 10.3858/emm.2010.42.1.006. View